Cancer CellPub Date : 2026-11-13DOI: 10.1016/j.ccell.2026.10.013
Laurence Zitvogel,Marine Fidelle,Guido Kroemer
{"title":"Antibiotics counteracting tumor-promoting dysbiosis in colorectal cancer","authors":"Laurence Zitvogel,Marine Fidelle,Guido Kroemer","doi":"10.1016/j.ccell.2026.10.013","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.013","url":null,"abstract":"Antibiotics usually sabotage immune checkpoint blockade. In this issue of Cancer Cell, Jiang et al. report that pulsed, anaerobe-directed metronidazole added to an anti-PD-1 antibody and a VEGF receptor inhibitor achieved encouraging progression-free survival in Fusobacterium nucleatum-positive microsatellite-stable metastatic colorectal cancer, selectively dismantling a pathobiont network without inducing global dysbiosis.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"71 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149398554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting F. nucleatum with metronidazole plus tislelizumab and fruquintinib in MSS colorectal cancer: A multicenter phase 2 study","authors":"Shanshan Jiang,Xiaolin Lin,Lekai Ni,Yanjie Zhang,Haoyan Chen,Chuan Liu,Haihua Yuan,Ziran Kang,Jiali Jiao,Ting Han,Meng Zhuo,Xiuqi Wu,Jingyi Zhou,Rongze Sun,Muni Hu,Zhixing Deng,Yichao Jiang,Chenyi Zhang,Pingping Xu,Peiying Li,Qi Li,Ying-Xuan Chen,Xiu-Ying Xiao,Jing-Yuan Fang","doi":"10.1016/j.ccell.2026.10.012","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.012","url":null,"abstract":"Fusobacterium nucleatum has been linked to chemoresistance and immune evasion in colorectal cancer (CRC), but therapeutic strategies targeting this bacterium remain limited. In this multicenter, single-arm, phase 2 trial (NCT06356597), 33 patients with Fusobacterium nucleatum-positive, microsatellite-stable metastatic CRC received the combination treatment of tislelizumab, fruquintinib, and the antimicrobial metronidazole. The primary endpoint was met, with a median progression-free survival of 6.0 months. The objective response rate and disease control rate were 19.4% and 83.9%, respectively. Grade 3 treatment-related adverse events occurred in 30.3% of patients, with no grade 4 or 5 events. Metagenomic analysis showed that metronidazole reduced Fusobacterium nucleatum abundance. Exploratory analyses associated clinical benefit with enrichment of Lactobacillus species and nonresponse with Enterococcus. Fecal microbiota transplantation from responders sensitized germ-free mice to the treatment, which enhanced cytotoxic CD8+ T cell differentiation and reduced terminal exhaustion. These findings support further evaluation of this combination in Fusobacterium nucleatum-positive metastatic CRC.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"29 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149398555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-11-09Epub Date: 2026-10-16DOI: 10.1016/j.ccell.2026.08.003
Derek De-Rui Huang, James Chih-Hsin Yang
{"title":"One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC.","authors":"Derek De-Rui Huang, James Chih-Hsin Yang","doi":"10.1016/j.ccell.2026.08.003","DOIUrl":"10.1016/j.ccell.2026.08.003","url":null,"abstract":"<p><p>EGFR PACC-mutant non-small cell lung cancer (NSCLC) has limited treatment options. In this issue of Cancer Cell, Le et al. report preclinical profiles and promising systemic and intracranial efficacy of the broad-spectrum CNS-penetrant tyrosine kinase inhibitor firmonertinib in PACC-mutant NSCLC, supporting its further clinical development in this challenging mutation class.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"2115-2117"},"PeriodicalIF":56.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-11-09DOI: 10.1016/j.ccell.2026.10.009
Shengduo Pei,Lai Guan Ng
{"title":"Neutrophils are known by their neighbors in breast cancer","authors":"Shengduo Pei,Lai Guan Ng","doi":"10.1016/j.ccell.2026.10.009","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.009","url":null,"abstract":"In this issue of Cancer Cell, Xu et al. combine large-scale computational pathology, spatial omics, and functional experiments to examine neutrophil organization in triple-negative breast tumors. They identify two neutrophil niches with different clinical associations: tumor-proximal neutrophils are linked to favorable prognosis, whereas neutrophils near immune cells associate with immunotherapy response.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"11 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Decoding neutrophil spatial heterogeneity and clinical implications in breast cancer","authors":"Yu-Zheng Xu,Xiang-Rong Wu,Zi-Yu Qiu,Yu-Wei Li,Lei-Jie Dai,Guan-Hua Su,Hang Zhang,Hu-Yun-Long Zhang,Ming Li,Hong Lv,Yi Xiao,Shen Zhao,Minhong Shen,Yi-Zhou Jiang,Ding Ma,Zhi-Ming Shao","doi":"10.1016/j.ccell.2026.10.005","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.005","url":null,"abstract":"Neutrophils are heterogeneous and critical components of the tumor microenvironment, yet their spatial heterogeneity and clinical implications remain poorly understood. We establish large-scale breast cancer cohorts integrating AI-powered computational pathology (n = 1,113) and single-cell spatial omics (n = 104) to investigate the clinical relevance and biological mechanisms underlying neutrophil spatial patterns. Clinical implications were greatest in triple-negative breast cancer (TNBC): neutrophil-tumor cell proximity associated with favorable prognosis, while neutrophil-immune cell proximity predicted superior immunotherapy response. Combining these patterns with established biomarkers improved TNBC stratification for prognosis and immunotherapy efficacy. Spatial omics and experimental validation demonstrated that tumor-proximal neutrophils enhanced MHC I expression on tumor cells via inflammatory crosstalk, promoting immune-mediated tumor clearance and improved prognosis. Neutrophils adjacent to immune cells exhibited an antigen-presenting phenotype, augmentable by targeting polyamine metabolism. Our study highlights the functional diversity and spatial heterogeneity of neutrophils and provides a translational strategy with routine computational pathology.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"16 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-11-09Epub Date: 2026-10-16DOI: 10.1016/j.ccell.2026.09.011
Xiuning Le, Jie Wang, Yan Yu, Yanqiu Zhao, David Planchard, Bo Gao, Alexander Spira, Jingling Liu, Xingya Li, Shirish Gadgeel, Natasha Leighl, Junqiang Zhang, Hidetoshi Hayashi, Makoto Nishio, Julien Mazieres, Adrianus Johannes de Langen, Maurice Pérol, Kiyotaka Yoh, Martin D Forster, Yasushi Goto, Maria de Miguel Luken, Fernando Fabio Franco Perez, Quincy Chu, Sagun Parakh, Monique B Nilsson, Yong Jiang, Tianhua Hu, Cunlin Wang, Nichole Baio, Luna Musib, Zineb Mounir, Marcin Kowanetz, Shirley Wang, Steven Yea, Jerry Hsu, Stuart Lutzker, John V Heymach, Oscar Juan-Vidal, Jonathan W Riess
{"title":"Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.","authors":"Xiuning Le, Jie Wang, Yan Yu, Yanqiu Zhao, David Planchard, Bo Gao, Alexander Spira, Jingling Liu, Xingya Li, Shirish Gadgeel, Natasha Leighl, Junqiang Zhang, Hidetoshi Hayashi, Makoto Nishio, Julien Mazieres, Adrianus Johannes de Langen, Maurice Pérol, Kiyotaka Yoh, Martin D Forster, Yasushi Goto, Maria de Miguel Luken, Fernando Fabio Franco Perez, Quincy Chu, Sagun Parakh, Monique B Nilsson, Yong Jiang, Tianhua Hu, Cunlin Wang, Nichole Baio, Luna Musib, Zineb Mounir, Marcin Kowanetz, Shirley Wang, Steven Yea, Jerry Hsu, Stuart Lutzker, John V Heymach, Oscar Juan-Vidal, Jonathan W Riess","doi":"10.1016/j.ccell.2026.09.011","DOIUrl":"10.1016/j.ccell.2026.09.011","url":null,"abstract":"<p><p>P-loop and αC-helix compressing (PACC) mutations comprise a structurally distinct subgroup of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) with limited treatment options. Firmonertinib is a once-daily oral, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor with a unique trifluoroethoxy side chain. Firmonertinib had high anti-proliferative efficacy in EGFR PACC-mutant cells and xenografts. In the phase 1b FURTHER study (NCT05364073), patients with metastatic EGFR PACC-mutant NSCLC randomized to receive first-line firmonertinib 160 mg (n = 25) or 240 mg (n = 22) had confirmed objective response rates (ORRs) of 43% and 68%, median duration of response not reached and 14.6 months, and median progression-free survival of 11.1 and 16.0 months, respectively; treatment-related adverse events led to dose reductions (19% and 24%) and discontinuation (3% and 0%). Intracranial ORR among patients with brain metastases at baseline was 47% (8/17). Results support further study of first-line firmonertinib in patients with EGFR PACC-mutant NSCLC.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"2267-2280.e5"},"PeriodicalIF":56.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-11-09DOI: 10.1016/j.ccell.2026.10.007
Dong Woo Kang,Jin Beom Bae,Seonho Yoo,Hyejin Kim,Pyunggang Kim,Jaewoo Mo,Jinhwan Kim,Jin Su Kim,Kwiyeom Yoon,Ye Seon Kim,Jeong Su Lee,June Myoung Kim,Min Gi Kang,Min Jung Lee,Changwon Lim,Isaac Y. Kim,Chang Pyo Hong,Junil Kim,John J. Letterio,Seong-Jin Kim
{"title":"A stroma-sensing TGF-β blockade reprograms CAF-myeloid niches to induce durable tumor immunity","authors":"Dong Woo Kang,Jin Beom Bae,Seonho Yoo,Hyejin Kim,Pyunggang Kim,Jaewoo Mo,Jinhwan Kim,Jin Su Kim,Kwiyeom Yoon,Ye Seon Kim,Jeong Su Lee,June Myoung Kim,Min Gi Kang,Min Jung Lee,Changwon Lim,Isaac Y. Kim,Chang Pyo Hong,Junil Kim,John J. Letterio,Seong-Jin Kim","doi":"10.1016/j.ccell.2026.10.007","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.007","url":null,"abstract":"Transforming growth factor β (TGF-β) accumulation in the tumor microenvironment (TME) is a major barrier to durable antitumor immunity. We developed fibronectin extra domain B (FN-EDB)-binding peptide (FEBP)-soluble TβRII-Fc (sTβRII), an engineered inhibitor targeting the FN-EDB-rich tumor matrix for localized TGF-β blockade. In fibrotic, immune-excluded tumors, FEBP-sTβRII suppresses TGF-β/SMAD signaling to unleash T cell activation and IFN-γ production, thereby driving feedforward cancer-associated fibroblast (CAF)-myeloid reprogramming toward an antigen-presenting state. This coordinated remodeling relieves immune exclusion and converts the fibrotic TME into an antigen-visible ecosystem that sustains robust T cell infiltration and activation. Consequently, FEBP-sTβRII induces T cell-dependent tumor regression, expands effector-memory populations, and elicits long-term, cross-protective antitumor immunity, while minimizing peripheral transcriptional disturbances compared with systemic sTβRII. Together, these findings show that spatially targeted TGF-β blockade overcomes fibrotic immune exclusion to establish durable local and systemic tumor immunity.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"9 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149367662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-11-06DOI: 10.1016/j.ccell.2026.10.010
Christina Yau, Laura J Esserman
{"title":"The future of early endpoints for neoadjuvant therapy.","authors":"Christina Yau, Laura J Esserman","doi":"10.1016/j.ccell.2026.10.010","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.010","url":null,"abstract":"<p><p>Early endpoints as surrogates for long-term outcomes are essential for treatment efficacy evaluation. In this issue of Cancer Cell, Conforti et al. report that CPS + EG and Neo-Bioscore scores predict long-term outcomes at the patient level but not at the trial level, highlighting the need for better early endpoints that reliably capture efficacy across trials.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":""},"PeriodicalIF":56.1,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-10-29DOI: 10.1016/j.ccell.2026.10.004
Anthony R. Sloan,George Bukenya,Gavin P. Tannish,Daniel J. Silver,Anu Aggarwal,Juyeun Lee,Daniel Rosoff,Tyler J. Alban,Ivan Juric,Shikha Parsai,Vargab Baruah,Tyler Bodovetz,Donovan Whitfield,Liza Tack,Tanvi Navadgi,Natalie Reitz,Shawn T. Ho,Aarav Badani,Jessica Goldberg,Xueer Yuan,Aymerick Gaboriau,Samrutha Kamatala,Jesse Coker,Vrishabhadev Sathish Kumar,Saachi S. Jain,Chang Xu,Alliefair Scalise,Bhairavi Rajasekar,Alex Vincenti,Erin E. Mulkearns-Hubert,Craig M. Horbinski,Andrew E. Sloan,Christopher G. Hubert,Jingqin Luo,Joshua B. Rubin,Evi X. Stavrou,Falk W. Lohoff,Wendy A. Goodman,Tyler E. Miller,Christine M. O’Connor,Marvin T. Nieman,Naseer Sangwan,Timothy A. Chan,Alok A. Khorana,Andrew Dhawan,Scott J. Cameron,Justin D. Lathia
{"title":"A sex-specific platelet switch controls anti-tumor immunity in glioblastoma","authors":"Anthony R. Sloan,George Bukenya,Gavin P. Tannish,Daniel J. Silver,Anu Aggarwal,Juyeun Lee,Daniel Rosoff,Tyler J. Alban,Ivan Juric,Shikha Parsai,Vargab Baruah,Tyler Bodovetz,Donovan Whitfield,Liza Tack,Tanvi Navadgi,Natalie Reitz,Shawn T. Ho,Aarav Badani,Jessica Goldberg,Xueer Yuan,Aymerick Gaboriau,Samrutha Kamatala,Jesse Coker,Vrishabhadev Sathish Kumar,Saachi S. Jain,Chang Xu,Alliefair Scalise,Bhairavi Rajasekar,Alex Vincenti,Erin E. Mulkearns-Hubert,Craig M. Horbinski,Andrew E. Sloan,Christopher G. Hubert,Jingqin Luo,Joshua B. Rubin,Evi X. Stavrou,Falk W. Lohoff,Wendy A. Goodman,Tyler E. Miller,Christine M. O’Connor,Marvin T. Nieman,Naseer Sangwan,Timothy A. Chan,Alok A. Khorana,Andrew Dhawan,Scott J. Cameron,Justin D. Lathia","doi":"10.1016/j.ccell.2026.10.004","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.10.004","url":null,"abstract":"Sex differences in glioblastoma (GBM) outcomes are shaped by biological, hormonal, and immune factors, but the mechanisms driving these disparities remain unclear. We identify platelet protease-activated receptor 4 (PAR4) signaling as a regulator of sex-specific anti-tumor immunity. GBM patients exhibit increased platelet reactivity driven by PAR4. In murine models, pharmacologic or genetic inhibition of PAR4 prolongs survival in females, but not males, and is estrogen dependent, persisting in hormonal females regardless of chromosomal sex. The survival advantage is mediated within the tumor microenvironment through enhanced CD8+ T cell infiltration and function. PAR4-activated platelets suppress CD8+ T cell activity, whereas CD8+ T cell depletion abolishes both tumor-induced platelet reactivity and the PAR4-dependent survival advantage. Mechanistically, PAR4 inhibition enhances CD8+ T cell signaling through interaction with estrogen receptor β (ERβ). These findings demonstrate that platelets are critical regulators of sex-specific anti-tumor immunity and identify PAR4 as a promising therapeutic target in cancer.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"21 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149281642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}